Purpose and Methods: Bone and soft tissue sarcomas currently comprise 1% of adult malignancies and 15% of pediatric malignancies [1]. While doxorubicin and ifosfamide are active agents, no significant impact on survival has been observed. More active regimes are required in sarcoma. This trial studied cisplatin and a 5 day continuous infusion of vinblastine for patients who had had disease progression of advanced soft tissue sarcoma after a doxorubicin based regimen.